Table 2 The clinical characteristics of patients based on whether pre-hepatectomy chemotherapy was performed or not
Oncologic scores ≥ 2 | Oncologic scores < 2 | |||||
|---|---|---|---|---|---|---|
Characteristics | Pre-hepatectomy chemotherapy | p value | Pre-hepatectomy chemotherapy | p value | ||
Yes N = 104 (%) | No N = 162 (%) | Yes N = 79 (%) | No N = 131 (%) | |||
Age (years), median (range) | 58 (29–86) | 61 (29–88) | 0.034 | 59 (29–84) | 62 (34–88) | 0.017 |
Gender | 0.201 | 0.601 | ||||
Male | 64 (61.5) | 112 (69.1) | 54 (68.4) | 94 (71.8) | ||
Female | 40 (38.5) | 50 (30.9) | 25 (31.6) | 37 (28.2) | ||
Primary tumor location | 0.337 | 0.336 | ||||
Right colon | 14 (13.5) | 29 (17.9) | 11 (13.9) | 25 (19.1) | ||
Left colon | 90 (86.5) | 133 (82.1) | 68 (86.1) | 106 (80.9) | ||
Type of initial hepatic metastases | 0.167 | 0.353 | ||||
Synchronous | 84 (80.8) | 141 (87.0) | 20 (25.3) | 26 (19.8) | ||
Metachronous | 20 (19.2) | 21 (13.0) | 59 (74.7) | 105 (80.2) | ||
Serum CEA (ng/mL), median (range) | 11.1 (0.5–16,259) | 13.4 (0.5–2954.0) | 0.190 | 7.0 (0.6–589.4) | 9.4 (0.9–170.5) | 0.849 |
Maximum tumor (cm), median (range) | 3.5 (0.6–14.5) | 3.3 (0.4–12.9) | 0.316 | 2.5 (0.8–10.0) | 2.5 (0.3–9.4) | 0.813 |
Tumor number, median (range) | 3.0 (1.0–17.0) | 1.5 (1.0–11.0) | 0.002 | 2.0 (1.0–7.0) | 1.0 (1.0–4.0) | 0.024 |
Primary lymph node | 0.959 | 0.387 | ||||
Positive | 89 (85.6) | 139 (85.8) | 38 (48.1) | 55 (42.0) | ||
Negative | 15 (14.4) | 23 (14.2) | 41 (51.9) | 76 (58.0) | ||